ArticleOcular oncology and pathology2025
The Association between Gene Expression Profiling and Regression Rate of Posterior Uveal Melanoma following Proton Beam Irradiation.
Article in Ocular oncology and pathology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: This study evaluated the association between gene expression profiling (GEP), PRAME (preferentially expressed antigen in melanoma), and regression rate of uveal melanoma after proton beam irradiation (PBI). Methods: A retrospective review of uveal melanoma patients treated with PBI between 2013 and 2021, with GEP results and at least 3 post-radiation ultrasound measurements, was conducted. Patients with local recurrences were excluded. Regression rates were analyzed using a linear mixed model to predict percentage change in thickness from baseline. Cox regression was conducted to determine whether slow or fast regression, based on the median regression rate at 18 months, correlates with metastasis risk. Results: The study included 106 patients, with GEP classifications of 1A in 43.4%, 1B in 25.5%, and 2 in 31.1%. Overall, the mean change in tumor thickness was 20.9%, 35.1%, 51.4%, and 59.3% at 1 year, 2 years, 4 years, and 6 years, respectively. No differences in regression rates between GEP classes and PRAME expression were found through 72 months post-PBI. The median regression at 18 months was 27.1%. Slow and fast regression was not associated with the risk of metastasis. Conclusion: No association between GEP, PRAME, and regression rate was found through 72 months post-PBI.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.